Brofaromine

drugbox
IUPAC_name = 4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine

---

CAS_number = 63638-91-5
ATC_prefix =
ATC_suffix =
PubChem = 44571
DrugBank =
C = 14 | H = 16 | Br = 1 | N = 1 | O = 2
molecular_weight = 310.186 g/mol
bioavailability =
protein_bound = 98%
metabolism =
elimination_half-life = 9 to 14 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Brofaromine is a reversible inhibitor of monoamine oxidase A primarily useful in the treatment of depression and anxiety. It is not commercially available and is not being actively researched, possibly due to a lack of financial interest.cite journal |author=Lotufo-Neto F, Trivedi M, Thase ME |title=Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression |journal=Neuropsychopharmacology |volume=20 |issue=3 |pages=226–47 |year=1999 |pmid=10063483 |doi=10.1016/S0893-133X(98)00075-X [http://www.nature.com/npp/journal/v20/n3/full/1395258a.html Free full text] ]

Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

References